Alternative treatments for oral bisphosphonate-related osteonecrosis of the jawsa pilot study comparing fibrin rich in growth factors and teriparatide

  1. Andrés Coca Pelaz
  2. Luis Manuel Junquera Gutiérrez
  3. Lorena Gallego López
  4. Luis García Consuegra
  5. Sonsoles Junquera
  6. Carlos Gómez Alonso
Revista:
Medicina oral, patología oral y cirugía bucal. Ed. inglesa

ISSN: 1698-6946

Ano de publicación: 2014

Volume: 19

Número: 4

Páxinas: 320-326

Tipo: Artigo

DOI: 10.4317/MEDORAL.19458 DIALNET GOOGLE SCHOLAR lock_openAcceso aberto editor

Outras publicacións en: Medicina oral, patología oral y cirugía bucal. Ed. inglesa

Obxectivos de Desenvolvemento Sustentable

Resumo

Objectives: The aim of this study is to describe and compare the evolution of recurrent bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients treated with plasma rich in growth factors or teriparatide. Material and Methods: Two different types of treatments were applied in patients diagnosed of recurrent BRONJ in a referral hospital for 1.100.000 inhabitants. In the group A, plasma rich in growth factors was applied dur - ing the surgery. In the group B, the treatment consisted in the subcutaneous administration of teriparatide. All the cases of BRONJ should meet the following conditions: recurrent BRONJ, impossibility of surgery in stage 3 Ruggiero classification and absence of diagnosed neoplastic disease. Clinical and radiographic evolution of the patients from both groups was observed. Results: Nine patients were included, 5 in group A and 4 in group B. All the patients were women on oral bis- phosphonate therapy for primary osteoporosis (5 patients) or osteoporosis-related to the use of corticosteroids (4 patients). Alendronate was the most common oral bisphosphonate associated with BRONJ in our study (four patients in group A and two in group B). The mean age was 72,8 years in the group A and 73,5 years in the group B. All the patients from group A showed a complete resolution of their BRONJ. Only one patient in the group B showed the same evolution. Conclusions: In our series, the plasma rich in growth factors showed better results than the teriparatide in the treatment of recurrent BRONJ.